[go: up one dir, main page]

NO20005535D0 - Pyrazol-derivater som P-38 MAP kinase-inhibitorer - Google Patents

Pyrazol-derivater som P-38 MAP kinase-inhibitorer

Info

Publication number
NO20005535D0
NO20005535D0 NO20005535A NO20005535A NO20005535D0 NO 20005535 D0 NO20005535 D0 NO 20005535D0 NO 20005535 A NO20005535 A NO 20005535A NO 20005535 A NO20005535 A NO 20005535A NO 20005535 D0 NO20005535 D0 NO 20005535D0
Authority
NO
Norway
Prior art keywords
kinase inhibitors
map kinase
pyrazole derivatives
methods
derivatives
Prior art date
Application number
NO20005535A
Other languages
English (en)
Other versions
NO317985B1 (no
NO20005535L (no
Inventor
Sharada Shenvi Labadie
David Mark Rotstein
Erik Brian Sjoegren
Francisco Xavier Talamas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20005535D0 publication Critical patent/NO20005535D0/no
Publication of NO20005535L publication Critical patent/NO20005535L/no
Publication of NO317985B1 publication Critical patent/NO317985B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/52—Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20005535A 1998-05-05 2000-11-02 Pyrazol-derivater som P-38 MAP kinase-inhibitorer NO317985B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8425098P 1998-05-05 1998-05-05
US12241099P 1999-03-02 1999-03-02
PCT/EP1999/002879 WO1999057101A1 (en) 1998-05-05 1999-04-28 Pyrazole derivatives as p-38 map kinase inhibitors

Publications (3)

Publication Number Publication Date
NO20005535D0 true NO20005535D0 (no) 2000-11-02
NO20005535L NO20005535L (no) 2000-11-02
NO317985B1 NO317985B1 (no) 2005-01-17

Family

ID=26770756

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005535A NO317985B1 (no) 1998-05-05 2000-11-02 Pyrazol-derivater som P-38 MAP kinase-inhibitorer

Country Status (22)

Country Link
EP (1) EP1075467B1 (no)
JP (1) JP3590586B2 (no)
KR (1) KR100404256B1 (no)
CN (1) CN1147476C (no)
AT (1) ATE292118T1 (no)
AU (1) AU765030B2 (no)
BR (1) BR9911013A (no)
CA (1) CA2329065A1 (no)
DE (1) DE69924480D1 (no)
HR (1) HRP20000724A2 (no)
HU (1) HUP0101581A3 (no)
ID (1) ID27535A (no)
IL (1) IL139169A0 (no)
MA (1) MA26627A1 (no)
NO (1) NO317985B1 (no)
NZ (1) NZ507558A (no)
PL (1) PL344004A1 (no)
RU (1) RU2000130199A (no)
TR (1) TR200003256T2 (no)
TW (1) TW593282B (no)
WO (1) WO1999057101A1 (no)
YU (1) YU67600A (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002528506A (ja) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
KR100609800B1 (ko) * 1998-12-16 2006-08-09 워너-램버트 캄파니 엘엘씨 Ｍｅｋ 저해제를 사용한 관절염 치료 방법
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6472528B1 (en) * 1999-08-10 2002-10-29 Neurocrine Biosciences, Inc. Synthesis of substituted pyrazolopyrimidines
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
JP2004504266A (ja) * 2000-01-17 2004-02-12 バイエル　アクチェンゲゼルシャフト 置換アリールケトン類
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2001232175B2 (en) 2000-03-03 2005-07-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
BR0111158A (pt) 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
CA2419820A1 (en) 2000-08-17 2002-02-21 Lumera Corporation Design and synthesis of advanced nlo materials for electro-optic applications
CZ20022642A3 (cs) * 2001-08-27 2003-09-17 Pfizer Products Inc. Způsob výroby dialkylpyridylboranů
CA2458808A1 (en) 2001-08-30 2003-03-13 F. Hoffmann-La Roche Ag Aminopyrrole compounds as antiinflammatory agents
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
KR101080393B1 (ko) * 2002-09-25 2011-11-07 우베 고산 가부시키가이샤 피라졸 화합물
RU2381219C2 (ru) * 2003-06-26 2010-02-10 Новартис Аг ПРОИЗВОДНЫЕ 5-ЧЛЕННЫХ ГЕТЕРОЦИКЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
PL1641764T3 (pl) 2003-06-26 2011-12-30 Novartis Ag Inhibitory kinazy P38 na bazie 5-członowych heterocykli
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
RU2419612C2 (ru) * 2003-12-23 2011-05-27 Астекс Терапьютикс Лимитед Производные пиразола в качестве модуляторов протеинкиназы
EP1758579A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
GB0513297D0 (en) * 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2008000777A2 (en) * 2006-06-29 2008-01-03 Glaxo Group Limited Phenyl- pyrazole derivatives, process for their preparation and their pharmaceutical use
GB0621978D0 (en) * 2006-11-03 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
PH12012500252A1 (en) 2009-08-07 2015-06-26 Chugai Pharmaceutical Co Ltd Aminopyrazole derivative
JP2011201794A (ja) * 2010-03-24 2011-10-13 Fujifilm Corp ５−アミノピラゾール誘導体及びその塩の製造方法
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
MX369974B (es) * 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
JP6514645B2 (ja) 2013-12-27 2019-05-15 中外製薬株式会社 Ｆｇｆｒゲートキーパー変異遺伝子およびそれを標的とする医薬
US10479780B2 (en) 2015-06-17 2019-11-19 Chugai Seiyaku Kabushiki Kaisha Aminopyrazole derivatives
GB201612238D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
WO2018059533A1 (zh) * 2016-09-29 2018-04-05 南京明德新药研发股份有限公司 p38αMAPK激酶抑制剂及其制备方法和应用
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3563848A1 (en) * 2018-04-30 2019-11-06 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Serpin inhibitors for the treatment of prion and prion-like diseases
GB201815699D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
GB201815695D0 (en) * 2018-09-26 2018-11-07 Mereo Biopharma 1 Ltd Synthetic method
US12421223B2 (en) * 2018-11-13 2025-09-23 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CN113166081A (zh) 2018-11-13 2021-07-23 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL175831B1 (pl) * 1992-12-17 1999-02-26 Pfizer Pochodna pirazolu

Also Published As

Publication number Publication date
CN1147476C (zh) 2004-04-28
JP3590586B2 (ja) 2004-11-17
ID27535A (id) 2001-04-12
HK1037374A1 (en) 2002-02-08
PL344004A1 (en) 2001-09-10
RU2000130199A (ru) 2002-11-10
CN1300282A (zh) 2001-06-20
DE69924480D1 (en) 2005-05-04
HUP0101581A2 (hu) 2002-03-28
HRP20000724A2 (en) 2001-06-30
KR100404256B1 (ko) 2003-11-01
NZ507558A (en) 2003-08-29
WO1999057101A1 (en) 1999-11-11
MA26627A1 (fr) 2004-12-20
CA2329065A1 (en) 1999-11-11
JP2002513784A (ja) 2002-05-14
TR200003256T2 (tr) 2001-04-20
BR9911013A (pt) 2001-02-06
NO317985B1 (no) 2005-01-17
ATE292118T1 (de) 2005-04-15
EP1075467A1 (en) 2001-02-14
HUP0101581A3 (en) 2002-07-29
TW593282B (en) 2004-06-21
KR20010043363A (ko) 2001-05-25
IL139169A0 (en) 2001-11-25
AU4034899A (en) 1999-11-23
AU765030B2 (en) 2003-09-04
EP1075467B1 (en) 2005-03-30
YU67600A (sh) 2003-07-07
NO20005535L (no) 2000-11-02

Similar Documents

Publication Publication Date Title
NO20005535L (no) Pyrazol-derivater som P-38 MAP kinase-inhibitorer
ATE267200T1 (de) Bicyclische kinase inhibitoren
BR0014225A (pt) Derivados de pirazol
MXPA02011320A (es) Derivados de pirazol triciclico como inhibidores de cinasa.
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
ATE300541T1 (de) Pyrazolopyridinderivate
AU2003228770A8 (en) Substituted pyrazolopyrimidines
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
ATE274515T1 (de) Pyrazolopyridinderivate
SE9904128D0 (sv) Novel compounds
ECSP992945A (es) Derivados de pirazol

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees